ZD-0892 AstraZeneca.

H, Ohbayashi

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2001

Data sources: Europe PubMed Central

ZD-0892 AstraZeneca.

descriptionPublicationkeyboard_double_arrow_right Article 19 Apr 2001 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 1 (issn: 1472-4472,

Copyright policy )

Authors: H, Ohbayashi;

pmid: 11249578

ZD-0892 AstraZeneca.

- Summary
- Subjects
- Metrics

Abstract

ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489]. The compound was originally under investigation for the potential treatment of asthma, but development was discontinued for this indication [266604]. The compound is the follow-up to ZD-8321 (qv) [336599].

Related Organizations

Nagoya University
Japan

Keywords

Clinical Trials as Topic, Sulfonamides, Drugs, Investigational, Asthma, Structure-Activity Relationship, Animals, Humans, Pyrroles, Anti-Asthmatic Agents, Enzyme Inhibitors, Leukocyte Elastase

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average